Monitoring Cancer Progression By Detecting Circulating Cancer Cells With Both Epithelial And Mesenchymal Features | 44581
Journal of Cancer Science & Therapy
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Isolation of circulating tumour cells (CTCs) from peripheral blood has the potential to provide an easier ‘liquid biopsy’ than tumour
tissue biopsies, to monitor disease progression and response to therapies at cell and molecular level. Previous studies on CTCs have
mainly focused on the identification of cytokeratin (CK)+/CD45- epithelial cells. However, epithelial to mesenchymal transition is a
critical step for tumour metastasis. We optimised a size-based platform, Parsortix, for the isolation of CTCs with both epithelial and
mesenchymal properties and developed a multiple FISH rehybridization method to analyse multiple genomic changes on the CTCs
after immunofluorescence signals were completely striped. Three types of CD45- potential circulating tumor cells, CK+/vimentin-,
CK+/vimentin+ and CK-/vimentin+, were detected. Genomic alterations were detected in a similar large proportion of cells in all
the three groups by analysing several genomic regions, indicating that the majority or all of those CK-/vimentin+/CD45-cells are
circulating prostate cancer cells under epithelial to mesenchymal transition. In addition, the number of CK-/vimentin+/CD45- CTCs
correlated better with cancer progression features than CK+ CTCs. Therefore, we developed a novel CTC detection and genomic
analysis approach, which can efficiently analyse both CK+ and CK-/vimentin+/CD45- cancer CTCs. This greatly enhances our ability
to investigate cancer metastasis process and using CTCs to monitor cancer progression and therapeutic response..
Yong-Jie Lu has completed his MD in 1992 and PhD in 1995. He did his Post-doctoral studies in Cancer Genetics at Institute of Cancer Research, London and set up his own research team for male urological cancer genetic and biomarker studies at Barts Cancer institute, Queen Mary University of London in 2003. He is a Reader in Medical Oncology at Queen Mary University of London. He has published more than 100 papers in reputed journals and has been serving as Editorial Board Member of a number on international scientific journals.